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Abstract
Oral administration of tumour cells induces an immune hypo-responsiveness known as oral tolerance. We have previously
shown that oral tolerance to a cancer is tumour antigen specific, non-cross-reactive and confers a tumour growth
advantage. We investigated the utilisation of regulatory T cell (Treg) depletion on oral tolerance to a cancer and its ability to
control tumour growth. Balb/C mice were gavage fed homogenised tumour tissue – JBS fibrosarcoma (to induce oral
tolerance to a cancer), or PBS as control. Growth of subcutaneous JBS tumours were measured; splenic tissue excised and
flow cytometry used to quantify and compare systemic Tregs and T effector (Teff) cell populations. Prior to and/or following
tumour feeding, mice were intraperitoneally administered anti-CD25, to inactivate systemic Tregs, or given isotype antibody
as a control. Mice which were orally tolerised prior to subcutaneous tumour induction, displayed significantly higher
systemic Treg levels (14% vs 6%) and faster tumour growth rates than controls (p,0.05). Complete regression of tumours
were only seen after Treg inactivation and occurred in all groups - this was not inhibited by tumour feeding. The cure rates
for Treg inactivation were 60% during tolerisation, 75% during tumour growth and 100% during inactivation for both
tolerisation and tumour growth. Depletion of Tregs gave rise to an increased number of Teff cells. Treg depletion post-
tolerisation and post-tumour induction led to the complete regression of all tumours on tumour bearing mice. Oral
administration of tumour tissue, confers a tumour growth advantage and is accompanied by an increase in systemic Treg
levels. The administration of anti-CD25 Ab decreased Treg numbers and caused an increase in Teffs. Most notably Treg cell
inhibition overcame established oral tolerance with consequent tumor regression, especially relevant to foregut cancers
where oral tolerance is likely to be induced by the shedding of tumour tissue into the gut.
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Introduction
Even allowing for comparable tumour stages the prognosis for
patients suffering from oesophageal and gastric cancer remains
consistently and significantly poorer than for patients with distal
gastrointestinal tract cancers, despite advances in diagnostic,
surgical and adjuvant therapies [1,2]. Among the many variables
that determine tumour growth rates and prognoses, differences in
tumour immune responsiveness are likely to exist between foregut
and other cancers. The processing of dietary antigens (Ags) by the
mucosal immune system in the gastro-intestinal tract leads to a
systemic Ag specific immune hypo-responsiveness termed oral
tolerance [3]. It is likely that tumour Ags derived from tumour
tissue shed into the intestine by foregut cancers would be processed
by the gut associated lymphoid tissues (GALT), predominantly
found in the proximal gastrointestinal tract, in a way reminiscent
of Ags ingested by the mucosal immune system, thus creating a
tumour Ag specific immune tolerance. We previously reported
that orally administered fresh tumour tissue induced a tumour Ag
specific non-cross-reactive immune tolerance with a consequent
growth advantage for the cancer [4].
The mechanism of tolerance to ingested Ags may be attributed
to either active suppression or the induction of clonal deletion/
anergy [5]. T cells cloned from tolerised mice have been ascribed
to a unique subset of the CD4+ population, the Th3 cell [6]. In T
cell receptor (TCR) transgenic mice, there was an increase in
CD4+CD25+ cells in response to oral Ag administration. These
Tregs were found to express CTLA-4 and foxp3 and to have a
suppressive function in vitro. CD4+CD25+foxp3+ Tregs play a role
in preventing the development of autoimmune disease and have a
dual property as both anergic and suppressive cells. Significantly, it
has been shown that removal of this population may induce anti-
tumour immune activity [7–10]. In experimental systems, as
tumours grow, there is a numerical increase in Tregs in the
immune infiltrate with consequent local suppression of the anti-
tumour immune responses. Antibody (Ab) mediated removal of
these Tregs can unmasks natural tumour immune reactivity and
this strategy has been shown to potentiate the immunotherapeutic
destruction of experimental cancers [10–12].
We have investigated the effects of oral tolerance to the JBS
tumour on tumour growth rates and on the size of lymphocyte
subpopulations in the Balb/C mouse. Specifically we examined if
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the induction of oral tolerance to tumours was Treg-dependent –
and whether Treg inactivation could abrogate oral tolerance and
inhibit tumour growth.
Materials and Methods
Cell Tissue Culture
The JBS murine fibrosarcoma [13] was grown in tissue culture
flasks at 37uC in a humidified atmosphere of 5% CO2, in DMEM
(Dulbecco’s Minimal Essential Medium –Sigma-Aldrich, Dublin,
Ireland). The tissue culture media were supplemented with 10%
iron-supplemented donor calf serum, 50 mg/ml gentamycin,
300 mg/ml L-glutamine, and 10 mM HEPES (1-Piperazineethane
sulfonic acid, 4-(2-hydroxyethyl) monosodium salt), pH 7.4.
Standard procedures for trypsinisation, centrifugation and resus-
pension of cells were used [13]. Viable cell counts were conducted
by using Trypan Blue Dye Exclusion (Sigma, Ireland).
Ethics Statement
All murine experiments were approved by the animal ethics
committee of University College Cork (AERR #2010/003). The
Figure 1. Schematic representation of experimental protocols. Initial experiments involved mice which were depleted of Tregs for the
duration of experiment and were referred to as being permanently depleted. For experiments involving depletion during tolerisation, Treg depletion
only occurred during tumour feeding and not when tumours were induced. The final protocol (depletion post tolerisation) required oral tolerance to
be established prior to Treg depletion.
doi:10.1371/journal.pone.0097602.g001
Figure 2. Subcutaneous tumour growth in immune-competent gavage fed mice. Growth curves for JBS tumours in mice following gavage
feeding for 14 consecutive days with JBS tumour homogenate or with PBS. JBS tumours grew significantly faster in mice orally tolerised with JBS.
Each point represents the mean tumour volume of a panel of six mice. The difference was statistically significant (p,0.05) at days 8, 9, 12 & 14 as
indicated by an asterix on the graph.
doi:10.1371/journal.pone.0097602.g002
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study was carried out in strict accordance with the recommenda-
tions laid down by the Irish Department of Children and Health.
Tumour Induction
Mice were obtained from Harlan Laboratories (Oxfordshire,
England). They were kept at a constant room temperature (22uC)
with a natural day/night light cycle in a conventional animal
colony. Standard laboratory food and water were provided ad
libitum. Before experiments, the mice were afforded an adaptation
period of 14 days. Balb/C mice of both sexes and athymic male
Balb/C HsdOla:MF1-nu mice in good condition, weighing 16–
22 g at 6–8 weeks of age, were included in experiments. For JBS
tumour induction, 26106 tumour cells, suspended in 200 ml
DMEM, were injected subcutaneously into the flank of the mice.
With this volume of inoculum and location there was little
puncture site extravasation of the cell suspension and the tumour
growth and shape was consistent.
Gavage Feeding
Following subcutaneous inoculation of 26106 JBS tumour cells
in Balb/C mice, tumours developed and were allowed to attain a
size of 1–2 cm3, at which stage the animals were sacrificed and
their tumours were removed. The tumours were homogenized in
phosphate buffered saline (PBS) (Sigma, Ireland) using a FastPrep
FP120 homogeniser (Thermo Electron Corp., England). The
homogenate was extensively washed by centrifugation with PBS to
remove debris. When the supernatant was macroscopically clear
the homogenate was resuspended in PBS to a final concentration
of 0.2 g (wet weight) per ml. This was aliquoted and frozen until
use. The PBS control was also aliquoted and frozen. Using an 18
Fr-steel-ball-tipped feeding needle attached to a 1 ml syringe, un-
anaesthetised animals were gavage fed 200 ml of freshly thawed
JBS tumour homogenate (40 mg of tumour) or PBS. Animals were
fed daily for 14 days. The amount of feed and the duration of
feeding corresponded to those used in previously published studies
by our group and were based on a literature review, particularly in
regard to studies that examined tolerance to cellular Ags [4,14–
17]. On day 15, animals received a subcutaneous inoculation of
tumour cells (26106 cells) and were monitored for tumour
development daily.
Tumour Monitoring
Tumours were measured every 48 hours using a digital calliper.
Tumour volume was calculated using the standard formula
v = ab2p/6 and tumour growth curves were constructed. The mice
were humanely euthanised in instances where the tumour reached
1.5 cm3 in diameter. In the first experiment, mice were fed tumour
Ag or PBS, and growth and survival curves were prepared. In the
second experiment, systemic Tregs were either permanently
inactivated (referred to as depleted) using anti-CD25 Ab (clone
PC61- Bio-Express, New Hampshire, USA), temporarily depleted
during feeding only or not depleted. In the final experiment mice
were fed for 14 days and subsequently randomised to receive anti-
CD25 Ab or a control Ab conjugated to anti-horse radish
peroxidase (HPRN), Bio-Express, USA to monitor the effect on sc
tumour growth.
Flow Cytometry Analysis
ACK erythrocyte lysing buffer (0.15 M NH4Cl, 10 mM
KHCO3, 0.1 mM Na2EDTA, pH 7.4 with HCl) was prepared
using reagents purchased from Sigma-Aldrich, Ireland. The
solution was filter sterilised through a 0.2 mm filter and stored at
4uC. FACS staining buffer was prepared from Dulbecco’s
phosphate-buffered saline (Dulbecco’s PBS) purchased from Sigma
along with, bovine serum albumin (BSA), sodium azide and foetal
calf serum. Spleens and tumour tissue were removed and minced
separately on 70 mm nylon cell strainer (BD Biosciences, UK).
These cell suspensions were collected, washed in culture medium,
pelleted at 300 g for 10 min at 4uC and were then treated with
ACK erythrocyte lysing buffer for 3 min after which they were
washed twice and resuspended in FACS staining buffer. Viable cell
numbers were determined by a standard Trypan Blue Exclusion
test. Cells were then diluted to a concentration of approximately
2–46106 per ml and 100 ml staining buffer added per Falcon tube
(Becton Dickinson). Cell suspensions and reagents were main-
tained at 4uC during preparation.
Cell Surface Marker Analysis
Phycoerythrin–Cy5 (PE-Cy5) conjugated antibodies against
murine CD25 and CD3, fluorescein isothiocyanate (FITC)-
conjugated antibodies against murine CD25, CD3, CD4 and
CD8 and the PE anti-mouse foxp3 staining kit were purchased
from eBioscience, Insight Biotechnology, England. PE anti murine
CD4 and CD3 were purchased from Serotec, Oxford, England.
Fluorochrome-conjugated isotype staining controls (FITC-IgG,
PE-IgG2a and PE-Cy5 IgG Isotype Control) were purchased from
eBioscience. Unconjugated anti-murine CD16/CD32 (Fcy III/II)
monoclonal Ab (Fc receptor blocking Ab) was purchased from
Serotec.
In order to minimise non-specific Ab binding, anti-CD16/
CD32 Fc receptor blocking Ab was diluted to 0.01 mg/ml in
staining buffer, 20 ml per well added and incubated at 4uC for
20 min. Fluorochrome-conjugated antibodies to cell surface
markers were also diluted as per manufacturer’s instructions and
were added to each sample without removal of the Fc-blocking
Ab. Cells were incubated in darkness at 4uC for 45 min then
washed twice in 250 ml staining buffer before resuspension in
500 ml staining buffer for immediate analysis or a fixative solution
of 0.5% paraformaldehyde in Dulbecco’s PBS. Analysis was
performed within 48 hours using a FACScaliber flow cytometer
(Becton Dickinson, Oxford, United Kingdom) and analysed by the
accompanying CELLQuest (BD Biosciences) computer software
program.
In Vivo Ab Administration
As previously stated, anti-CD25 Ab (PC61) and control Ab
(isotype control rat IgG-HRPN) were administered intra-perito-
nealy at a dose of 1 mg/kg in a total volume of 200 ul of PBS. The
Figure 3. Peripheral Treg numbers in mice gavage fed tumour or PBS. (a) Dot plots show the number of peripheral blood Tregs in PBS (i–iv)
or JBS (v-,viii) fed mice. Tregs were stained using CD3, CD4, CD25 and foxp3 antibodies conjugated to fluorochromes and isotype controls and
analysed on the flow cytometer. The cells were gated on CD3+ and CD4+ (ii and vi) and isotype controls (i and v) and subsequent dot plots were
acquired through this gate for CD25+ and foxp3+ cells (iv and viii) and isotype controls (iii and vii). There was a significant increase in CD4+CD25+ cells
(p,0.022) following tumour administration versus PBS. Moreover there was a significant increase observed in CD25+/foxp3+ expression following
gating on the CD3+CD4+ population of lymphocytes (p,0.019). (b) Graph representing the mean percentage values of Treg numbers minus the
isotype controls within the total peripheral lymphocyte population from JBS or PBS fed mice. There was significantly more Tregs in the spleens of
mice that were fed homogenised tumour for 14 days than those fed PBS alone (p,0.002; n = 6).
doi:10.1371/journal.pone.0097602.g003
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Figure 4. Tumour growth and survival following anti-CD25 Ab. (a) There was no significant difference between tumour growth rates
between mice fed tumour (temporarily or permanently) and control mice. Mice which received no anti-CD25 Ab depletion showed significantly
different tumour growth rates at days 14, 18 and 22 depending on whether they had been fed tumour and saline (p,0.05). Each data point
represents mean tumour values for 10 mice. (b) Survival curve for mice that were permanently, temporarily or not depleted during the induction of
oral tolerance. Mice that were permanently depleted were 100% cured of their subcutaneous tumour and remained disease free at 100 days. 75% of
those that were temporarily depleted while fed tumour were cured, while 66% of those that were temporarily depleted and fed PBS cured. There was
no significant difference between these groups. All of those mice that received isotype control Ab succumbed to tumour burden (n = 10).
doi:10.1371/journal.pone.0097602.g004
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timing of doses depended on the experimental protocol but when
two doses were to be administered they were given four days apart
(Fig. 1). This resulted in over 95% inactivation of Tregs as
determined by flow cytometry.
Statistical Analysis
The differences between the individual groups were tested using
the two-tailed Student’s t-test for paired values. Differences with a
p value less than 0.05 were considered significant.
Results
Oral Administration of Tumour Tissue Confers a Tumour
Specific Growth Advantage
We have previously shown that subcutaneous tumours have a
faster growth rate in mice that were fed tumour prior to tumour
induction, compared with mice that were fed either PBS or an
alternative tumour (CarB or CT26) [4,13]. We have also
demonstrated that the tumour growth curve in Balb/C mice
approximates the growth curve of subcutaneous tumour in
athymic nude mice, which lack functioning T cells and these
mice were used as an immune incompetent control [13]. In this
study, using the same feeding protocol, we validated that our
tumour feeding regime resulted in a consistent and significantly
increased subcutaneous tumour growth rate in Balb/C mice versus
control groups. Subcutaneous tumours in the groups fed JBS
tumour appeared earlier (day 5 vs. day 6/7) and grew significantly
faster (p,0.05) at several time points (Fig. 2).
Flow cytometry analysis of lymphocytes in response to
tumour ingestion
Following 14 days of oral tumour or PBS administration, splenic
lymphocyte populations were analysed. There was a significant
increase in CD4+CD25+ cells (p,0.022) following tumour
administration versus PBS. Moreover there was a significant
increase observed in CD25+/foxp3+ expression following gating on
the CD3+CD4+ population of lymphocytes (p,0.019) (Fig. 3).
There was no significant increase in total numbers of CD3+CD4+
or CD3+CD25+ cells. Neither was there any significant increase in
the CD8+CD25+ Teff sub-group populations following the tumour
feeding schedule. There was no observable difference in the
number or ratio of lymphocyte populations between those mice
which were fed PBS and those not gavage-fed during this period
(data not shown).
Increased Tumour Growth Rate is Associated with the
Activity of Tregs
We have previously shown that our anti-CD25 Ab administra-
tion protocol facilitates 90% inactivation of CD25+ cells over a
period of 14 days [8]. Mice were randomised to receive either anti-
CD25 Ab at the commencement of the 14-day feeding schedule,
and again at the end of feeding (referred to as permanent
depletion) or Ab at the time of commencing feeding only (referred
to as depletion during tolerising) or control Ab, or no Ab (Fig. 1).
The resulting subcutaneous tumour growth curves showed that
the previously observed tumour growth advantage following
feeding was absent in mice undergoing the depletion during the
tolerising schedule, with time to tumour appearance and tumour
growth rate similar to PBS-fed mice, indicating the requirement
for Tregs at the time of tumour feeding for the induction of oral
tolerance (Fig. 4a). As seen in Fig. 4b, tumours in mice receiving
anti-CD25 Ab eventually regressed completely, both in depletion
during tolerisation and permanent depletion groups. We, and
others, have previously reported the finding that anti-CD25
administration prior to tumour induction induces complete
tumour regression [8].
Changes in Lymphocyte Sub-populations Observed in
Response to the Depletion of Tregs Either Permanently
or During Tolerisation
At various time points, mice from each group were sacrificed
and their spleens analysed for systemic CD4+CD25+ Treg and
CD8+CD25+ Teff numbers. Tumour feeding significantly in-
creased systemic Treg numbers versus PBS fed groups, and this
difference was also seen in anti-CD25 Ab administered mice
(Fig. 5a) (p,0.01). While there were significantly lower numbers of
Tregs in PBS-fed groups that received anti-CD25 Ab than those
who received control Ab (Fig. 5b) (p,0.05), surprisingly, a
reduction in overall Treg numbers was not found in anti-CD25
Ab, tumour-fed mice.
We also examined the effect of oral tolerance and anti-CD25
Ab on the systemic activated effector lymphocyte population,
namely the CD8+CD25+ cells. There was an increase in the
number of Teff cells that were permanently depleted and fed
tumour compared with all other groups (Fig. 6) and this value was
approaching significance.
Anti-CD25 Ab Therapy Post-tumour Feeding Overcomes
the Induced Oral Tolerance
To determine whether anti-CD25 Ab therapy can abrogate an
established tumour growth advantage, mice which had completed
the oral tumour feeding schedule were randomly divided into
groups to receive anti-CD25 Ab versus control Ab or no Ab (PBS
alone). Administration of anti-CD25 Ab immediately following
tumour feeding, removed the previously observed tumour growth
advantage (Fig. 7a). This was found to be significant when
compared with the other groups (p,0.03). Survival data showed
that 100% of mice which received anti-CD25 Ab were cured, a
Figure 5. Splenic Tregs following feeding and Ab therapy. (a) Cells were stained for CD3, CD4 and CD25. The cells were initially gated on CD3
and subsequently on CD4+CD25+. Splenic Tregs were analysed from mice which had been treated with (i) isotype control antibody followed by PBS
feeding; (ii) temporarily depleted with anti-CD25 antibody but PBS fed (iii) permanently depleted with anti-CD25 antibody and PBS fed; (iv) isotype
control antibody treatment and tumour fed, (v) temporarily depleted with anti-CD25 but tumour fed or (vi) permanently depleted and tumour fed.
Representative dot plots from relevant groups are shown, three mice from each treatment group were analysed; (b) Graph representing the mean
data from the dot plots in (a). There is a significant difference between those mice that were tumour fed or PBS fed and permanently depleted with
anti-CD25 (p,0.01), depletion during tolerisation while PBS or JBS fed (p,0.001), control Ab, tumour fed versus control Ab, PBS fed (p,0.01). There
was a significant difference between those mice that were treated with control Ab or PBS fed and those that were treated with anti-CD25 Ab at any
time and PBS fed, (p,0.05). There was no significant difference in Tregs between any of those mice that were tumour fed across the treatment
groups.
doi:10.1371/journal.pone.0097602.g005
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cure rate equivalent to the group of mice not fed tumour and
subsequently treated with anti-CD25 Ab (Fig. 7b).
Treg Numbers in Cured Mice
The anti-CD25 Ab treatment did not have long term effects on
Treg numbers. Mice cured of their tumours through anti-CD25
administration were studied 30 days later and had similar Treg
numbers to naı¨ve animals irrespective of whether they were from
the orally tolerised or control groups (Fig. 8).
Discussion
Most patients who develop cancers of the upper gastrointestinal
tract die as a direct consequence of their disease. Even for those
with clinically localized tumours, who are subjected to curative
surgery, the five year relapse rates are usually above sixty percent
[18]. At the time of surgery, most of these patients have
micrometastases in various tissues indicating haematogenous
spread of the cancer at an early stage of tumour development.
This leaves patients in a minimal disease state post-surgical
treatment. A therapy that could facilitate the immune system to
identify tumour Ags systemically would be ideal, if not to clear all
of the disease burden, then at least to create a state of tumour
dormancy [19,20].
We have previously shown that growth of the weakly
immunogenic JBS cell line in the flank of immune competent
mice led to an increase in Treg cell numbers in the tumour
environment but not systemically [8]. In this study we have
modelled the presence of tumour fragments in the gut to the
clinical situation by gavage feeding of JBS cells to mice. We would
expect these fragments to be processed by the GALT and would
result in a systemic hypo-responsiveness to tumour Ags [13]. We
have demonstrated for the first time that CD4+CD25+ Tregs are
systemically increased in response to oral administration of whole
(JBS) tumour. In addition we have shown that the induction of oral
tolerance to a tumour confers a growth advantage to the cancer.
Mice whose Tregs were depleted by anti–CD25 treatment,
irrespective of tumour or PBS feeding, demonstrated regression of
tumours and long term cures. There were no differences in
response rates between the tumour fed and control groups
indicating that Treg inhibition effectively overcomes the combined
oral tolerance and tumour growth influences. It is likely that the
early induction of Tregs at the systemic level, achieved in this
study by tumour feeding, is responsible for the tumour growth
advantage observed. It is of interest that there were no differences
in the numbers of CD8+ T cells between any of the groups
suggesting that a reduction in Teffs does not occur with oral
tolerance induction. It is also likely that oral tolerance and early
Treg responses did not inhibit immune sensitisation to the tumour
but inhibited effector function as there were no differences in the
timing or completeness of tumour regression after Ab treatment
between the tumour fed tolerised or the PBS control group of
mice. There was a significant difference in the total number of
CD4+CD25+ Tregs in mice which received anti-CD25 Ab and
were tumour fed and the control saline fed groups. This was also
observed in those groups which were temporarily depleted.
Surprisingly however, there was no significant decrease in Tregs
observed between the groups that were tumour fed and received
either a dosing schedule of anti-CD25 Ab or isotype control Ab. A
possible explanation for this may be due to the analysis of Treg
numbers using CD4+CD25+ only at this stage of the experimental
process as opposed to the more specific CD4+CD25+foxp3+. No
significant decrease in Tregs may in fact involve the experimental
protocol and the timing for examination of Tregs and dose of anti-
CD25Ab, which was chosen based on our previous knowledge that
maximum Treg depletion was within 7 days of Ab administration.
The dose of Ab used in this study ensured a 90% reduction in Treg
numbers in naı¨ve mice. The overall increase in Treg numbers in
response to feeding was not taken into consideration with an
increased dose of Ab. Despite this, functional differences between
different doses of anti-CD25 Ab were observed in the resulting
growth curves, suggesting CD4+CD25+ Treg cells are involved in
the T cell response that confers the tumour growth advantage
following feeding. This may be due to the fact that the effect of
removing or functionally inactivating Tregs with Ab depletions
during the development of oral tolerance is enough to allow for
partial education of the immune system and the development of
anti-tumour cytotoxic responses. Interestingly, there were more
cures seen in the groups that were given anti-CD25 Ab at the time
of feeding only and fed tumour (75%) than in those given Ab at the
time of feeding and fed PBS (60%). It may be that Ag loading with
feeding and subsequent inactivation of Tregs giving rise to
increased Teff numbers could have occurred and similar findings
have been demonstrated elsewhere [21].
In the clinic, patients with GALT present with an already orally
tolerised immune system, and it remains to be determined whether
oral tolerance can be overcome after tumour growth has been
established. In studies of tolerance, it has been shown that the
adoptive transfer of Tregs into murine models can overcome
immune mediated disease [5]. In this study, we examined whether
the removal of Tregs can allow the development of a cytotoxic T
cell response to a subcutaneous tumour. Following the feeding of
tumour and establishment of oral tolerance, a single dosing
schedule of anti-CD25 Ab removed the tumour growth advantage
that would normally be seen in the absence of anti-CD25 Ab
treatment. Moreover, the administration of anti-CD25 Ab led to
cures in all mice harbouring subcutaneous tumours. We have
shown that even an established oral tolerance to a tumour Ag, and
the resulting aggressive tumour growth and poorer survival, can be
overcome by Treg attenuating therapy. This result suggests that
cancers of the upper gastrointestinal tract would be amenable to
therapies that attempt to inactivate established Treg cell activity. It
is also important to note that anti-CD25 Ab therapy did not affect
the systemic Treg populations in treated mice following therapy,
compared with naı¨ve mice. This is important as it limits the
possibility that anti-CD25 Ab therapy of autoimmune diseases
could remove Tregs entirely or permanently.
Figure 6. Splenic Teff cells following feeding and Ab therapy. (a) Spleens from mice in each treatment group were stained to determine
CD3+/CD8+ and CD3+/CD25+ numbers. Groups were as follows (i) tumour fed but no antibody depletion; (ii) PBS fed and no antibody depletion; (iii)
PBS fed and anti-CD25 treated and (iv) tumour fed, anti-CD25 treated. CD8+ and CD25+ were examined from within the CD3+ population. Each
experiment was performed in triplicate; (b) Graph representing the changes in Teff numbers following tumour feeding and Ab depletions.
Cumulative data from dot plots represented in (a) (n = 3).
doi:10.1371/journal.pone.0097602.g006
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Figure 7. Anti-CD25 Treg depletion therapy overcomes established oral tolerance. (a) Mice were fed tumour or PBS and randomly
assigned to receive anti-CD25 Ab, isotype control Ab or PBS. Those which received anti-CD25 Ab had slower tumour growth rate compared to the
other groups. The significant difference in growth rate between those that were tumour or PBS fed was maintained in the isotype control Ab and no
Ab groups at certain time points (p,0.05); (b) Mice that were tolerised to tumour antigen through oral administration of tumour were subsequently
treated with anti-CD25 Treg depletion treatment and were cured of their subcutaneous tumour remaining tumour free for at least 100 days.
doi:10.1371/journal.pone.0097602.g007
Tregs Abrogate Oral Tolerance to Cancer
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The results of this study suggest a mechanism of tolerance – a T-
cell-mediated suppression of an antitumour immune response.
The identity of the tumour Ag(s) has yet to be established;
however, this study confirms and expands on observations of
previous reports where feeding of tumour Ags was shown to impair
antitumour cytotoxicity and thus supports the hypothesis that
tumour Ags which are shed into the upper gastrointestinal tract
and processed by the mucosal immune system may result in down
regulation of systemic antitumour immune responses [3,22].
We have shown that processing of the shed tumour results in the
generation of immunosuppressive Treg cell population which can
attenuate the antitumour immune response and that the develop-
ment of oral tolerance in this clinically based model is Treg-
dependent. Moreover, we demonstrate that the abrogation of Treg
cell function can be achieved with the use of anti-CD25 Ab giving
rise to a systemic, non-toxic, effective anti-tumour response. Our
studies show that immune modulatory effects may contribute to
the significantly poorer prognosis in foregut cancers and may be
overcome by immune therapy, representing a significant potential
advance in the development of more effective therapies against
these diseases. Anti-CD25 Treg depletion therapy has the capacity
to improve prognosis and confer a survival advantage on patients
with oesophageal and gastric cancers.
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